David Muus

David Muus studied law at Groningen University. David further completed post-graduate education in IP and IT law at Grotius Academy and has received education in communication protocols, with a focus on mobile- and IP-networks.

Before joining Sisvel in 2015, he acted as IP counsel and patent licensing specialist at the Dutch incumbent telecom operator KPN. At Sisvel, David started out from Turin and London where he ran Sisvel’s LTE patent pool and its successor the Mobile Communication Program (MCP). Since 2019 David works from Sisvel’s Barcelona office at the head Sisvel’s cellular team, where he is responsible for all of Sisvel’s cellular SEP licensing activities. This includes Sisvel’s bilateral licensing and litigation activity under the cellular SEPs Sisvel controls, as well as the management of two recently launched patent pools: the 5G Multimode Program, the next generation of the MCP which now focusses on 5G enabled consumer electronics, and Sisvel’s Cellular-IoT program, focused on licensing IoT devices enabled with the LPWAN standards Narrowband-IoT and LTE-M.

When AI Helps Generate Inventions, Who Is the Inventor?

By Andrei Iancu and Rama Elluru This commentary from the CSIS-SCSP Task Force on IP in the AI Era was originally published in the Special Competitive Studies Project’s Substack on February 15, 2024. With roots in the U.S. constitution, patent rights provide an exclusive property right in new inventions like drugs,
Read More

Standard Essential Patents and European Economic Security

By Kirti Gupta and Chris Borges On April 27, 2023, the European Commission published a draft proposal on standard essential patents (SEPs) seeking to address the perceived lack of transparency and predictability in the licensing of SEPs. The commission proposes the creation of a competence center within the European Union Intellectual
Read More

Proposed Federal Use of March-in Rights Would Weaken American Innovation

By Sujai Shivakumar and Thomas Howell   The Biden administration is considering exercising something called “march-in rights” as a policy prescription to curb drug prices. But as with any prescription, there is a need to weigh efficacy against the side-effects. In this case, there is evidence that the vast majority of
Read More